The notices it replaced
- Reissues: PAR-21-329 Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
- 2 steps back: PAR-19-325 Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Who won it before
33 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $17,424,723 in first-year total cost, median $599,204.
Most frequent study sections
- Radiation Therapeutics and Biology Study Section[RTB]5
- Special Emphasis Panel[ZRG1 BDCN-Q (55)]3
- Human Complex Mental Function Study Section[HCMF]2
- Neurobiology of Pain and Itch Study Section [NPI]2
- Brain Injury and Neurovascular Pathologies Study Section[BINP]1
Most frequent institutions
- UNIVERSITY OF CALIFORNIA-IRVINE4
- SLOAN-KETTERING INST CAN RESEARCH3
- DUKE UNIVERSITY2
- CHILDREN'S HOSP OF PHILADELPHIA1
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Development of a Personalized Voxel-wise Prediction of Brain Metastases using Multi-Parametric MR Imaging to Reduce Treatment Toxicity1R01CA292043-01A1 · under PAR-21-329 | BRAUNSTEIN, STEVE EMORIN, OLIVIER | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $729,587 | CDMA |
| 2025 | Mechanisms of Radiation-Induced Neurocognitive Decline (MIND): Longitudinal Study of Imaging Biomarkers and Risk and Resilience Factors Underlying Cognitive Phenotypes in Patients with Glioma1R01CA289833-01A1 · under PAR-21-329 | HATTANGADI-GLUTH, JONA AMCDONALD, CARRIE R | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $667,485 | HCMF |
| 2025 | Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease1R01CA305985-01 · under PAR-21-329 | BEVERLY, LEVI JSISKIND, LEAH J | UNIVERSITY OF LOUISVILLE, KY | $649,021 | PBKD |
| 2025 | Mechanistic Insight to Predict and Prevent Nilotinib-Induced Artery Disease1R01CA292427-01A1 · under PAR-21-329 | BURRIDGE, PAUL W.SAPKOTA, YADAV | NORTHWESTERN UNIVERSITY, IL | $645,460 | GHD |
| 2025 | Non-invasive, quantitative microscopic biomarkers for chemotherapy-induced peripheral neuropathy1R01CA301271-01 · under PAR-21-329 | KANG, DONGKYUN | UNIVERSITY OF ARIZONA, AZ | $391,325 | CTIS |
| 2024 | Genomics-based Mechanistic Investigation of Cancer-treatment Related Cardiotoxicity among Survivors of Childhood Cancer1R01CA290112-01 · under PAR-21-329 | WANG, ZHAOMING | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $683,650 | CHD |
| 2024 | Investigating the Pathogenic Role of Tubulin Post-translational Modifications in CIPN1R01CA279401-01A1 · under PAR-21-329 | BARTOLINI, FRANCESCA | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $661,122 | NPI |
| 2024 | Comprehensive Molecular and Clinical Characterization of Acute and Chronic Neurotoxicity Following CAR-T Cell Therapy1R01CA293922-01 · under PAR-21-329 | SANTOMASSO, BIANCA DENISE | SLOAN-KETTERING INST CAN RESEARCH, NY | $610,197 | CONC |
| 2024 | Identification of novel biomarkers and therapeutic strategies in chemobrain.1R01CA293210-01 · under PAR-21-329 | COLE, PETER D.JANG, MI-HYEON | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $593,617 | CNBT |
| 2024 | Reducing toxicity from prostate cancer radiotherapy through genetics and technology1R37CA292795-01 · under PAR-21-329 | KISHAN, AMAR U | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $360,281 | RTB |
| 2024 | Countering microtubule stabilization within hair follicles in ovarian cancer chemotherapy1R01CA286527-01 · under PAR-21-329 | XU, XIANGXI MIKE | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $351,131 | ZRG1 |
| 2024 | Cellular basis for cancer treatment related GDF15 expression and the regulation of skeletal muscle fibrosis and neuromuscular integrity.1R01CA290724-01 · under PAR-21-329 | CHAKKALAKAL, JOE | DUKE UNIVERSITY, NC | $344,059 | ZRG1 |
| 2023 | The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis1R01CA276352-01A1 · under PAR-21-329 | FREEMAN, MICHAEL L.WEST, JAMES D | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $725,891 | RTB |
| 2023 | Targeting neuronal transport to ameliorate vincristine neurotoxicity1R01CA272254-01A1 · under PAR-21-329 | BAKER, SHARYN DHU, SHUIYINGPETERSON, BLAKE | OHIO STATE UNIVERSITY, OH | $645,896 | DMPB |
| 2023 | Preclinical and Clinical Models of Drug Induced Kidney Injury1R01CA277313-01A1 · under PAR-21-329 | ALEKSUNES, LAUREN MJOY, MELANIE S | UNIVERSITY OF COLORADO DENVER, CO | $637,693 | DBDT |
| 2023 | Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial1R37CA273923-01A1 · under PAR-21-329 | YU, ANTHONY FRANCIS | SLOAN-KETTERING INST CAN RESEARCH, NY | $634,233 | CCHS |
| 2023 | Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms1R01CA272147-01A1 · under PAR-21-329 | DAMAJ, M. IMADSELLEY, DANA ESIM-SELLEY, LAURA J | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $613,882 | NPI |
| 2023 | Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy1R37CA277043-01 · under PAR-21-329 | HERTZ, DANIEL LOUISTRIVEDI, MEGHNA S | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $601,172 | XNDA |
| 2023 | Radiation-Induced Fibrosis and Co-occurring Adverse Treatment-Related Effects in Head and Neck Cancer Survivors1R37CA279210-01A1 · under PAR-21-329 | NILSEN, MARCI LEE | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $599,204 | ICSC |
| 2023 | Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity1R01CA275870-01 · under PAR-21-329 | STAFF, NATHAN P | MAYO CLINIC ROCHESTER, MN | $579,394 | NAL |
| 2023 | Neurotrophic strategy to mitigate chemotherapy-related brain injury1R01CA276212-01A1 · under PAR-21-329 | ACHARYA, MUNJAL MCHAN, ALEXANDRE | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $471,019 | ZRG1 |
| 2023 | Stem cell-derived exosomes to ameliorate chemobrain1R01CA262213-01A1 · under PAR-21-329 | ACHARYA, MUNJAL M | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $359,138 | ZRG1 |
| 2023 | Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction1R37CA282349-01 · under PAR-21-329 | STOLARZ, AMANDA | UNIV OF ARKANSAS FOR MED SCIS, AR | $351,977 | IVPP |
| 2023 | Prospective international phase-III study to improve neurocognitive outcomes in young children with low-risk medulloblastoma (YCMB-LR)1R01CA283045-01 · under PAR-21-329 | SANDS, STEPHEN ALAN | SLOAN-KETTERING INST CAN RESEARCH, NY | $265,699 | HCMF |
| 2022 | Fingolimod and Ozanimod for the treatment and prevention of chemobrain1R01CA261979-01A1 · under PAR-19-325 | FARR, SUSAN ASALVEMINI, DANIELA | SAINT LOUIS UNIVERSITY, MO | $442,415 | ZRG1 |
| 2022 | Developing mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy1R37CA267905-01 · under PAR-19-325 | GEISLER, STEFANIE | WASHINGTON UNIVERSITY, MO | $419,474 | CNNT |
| 2021 | Intensive tailored exercise training with NAD+ precursor supplementation to improve muscle mass and fitness in adolescent and young adult survivors of hematopoietic stem cell transplantation1R01CA254955-01A1 · under PAR-19-325 | MCCORMACK, SHANA ERINMOSTOUFI-MOAB, SOGOL | CHILDREN'S HOSP OF PHILADELPHIA, PA | $771,376 | CHSA |
| 2021 | Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system1R01CA263806-01 · under PAR-19-325 | BOTA, DANIELA ANNENELIEGUPTA, KALPNA | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $634,722 | ZRG1 |
| 2021 | Glial immune signaling in radiation-induced brain injury1R01CA251110-01A1 · under PAR-19-325 | ACHARYA, MUNJAL M | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $419,984 | RTB |
| 2021 | Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities1R01CA251136-01A1 · under PAR-19-325 | HANKS, BRENT ALLEN | DUKE UNIVERSITY, NC | $396,432 | ZRG1 |
| 2021 | Chemotherapy-induced vascular cognitive impairment: role of endothelial senescence1R01CA255840-01 · under PAR-19-325 | CSISZAR, ANNA | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $331,688 | BINP |
| 2021 | Characterization of the cellular mechanisms of radiation induced brain necrosis for clinical intervention1R01CA255596-01A1 · under PAR-19-325 | GROSSHANS, DAVID R | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $174,886 | RTB |
| 2020 | Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy and Immunotherapy1R01CA252484-01 · under PAR-19-325 | LU, BO | THOMAS JEFFERSON UNIVERSITY, PA | $661,613 | RTB |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.